Category: News

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In February, Cyan Investment Management’s Graeme Carson selected logistics business Silk Logistics Holdings as one of his favourite stocks, highlighting the company’s $90 million (FY14) to $394 million (FY22) jump in revenue and founder-led management.

With fears of a global banking crisis after the Silicon Valley Bank and Signature Bank collapses, UBS has come to the rescue of Credit Suisse, acquiring the troubled bank for 3 billion Swiss francs ( AUD $4.5 million).

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has announced continued promising data for its targeted therapy PTX-100, after releasing Phase 1b trial data that showed a wealth of positive data – including two complete responses in patients with relapsed and refractory (r/r) Peripheral T-cell Lymphoma (PTCL). This data comes on the heels of a recent announcement by the US Food and Drug Administration (FDA) to grant PTX-100 Orphan Drug Designation for all T-cell lymphomas.  The company is now expanding the trial in preparation for a Phase 2 Accelerated Approval trial.

Thinking of ‘cycling through the streets of Paris’ paints a near perfect picture of charming laneways with an abundance of cafés, the sounds of an accordion bouncing off stone buildings rich with architecture and – if one business owner has anything to do with it – funerals.

Aussie junior explorer Far East Gold (ASX: FEG) has identified visible gold and electrum within a drill core from the Rek Renti prospect area within its Woyla tenement – a project touted by the company to be one of the most highly prospective undrilled copper gold projects in South East Asia.

Customer-focused healthcare company Wellnex Life (ASX: WNX) has announced that it has added Australian pharmaceutical giant Chemist Warehouse to its SAS-B medicinal cannabis joint venture (JV) with OneLife Botanicals, and will be launching five new products throughout Chemist Warehouse’s extensive network. 

Markets have rapidly readjusted their expectations of the terminal rates for many major world economies in the fallout from the Silicon Valley Bank Collapse (SVB). Forecasts of another 50 basis point rate hike by the Fed later this month have dropped to 40% (down from 80%), and the RBA’s peak is now priced in at 3.9%, down from 4.1%. Traders now place a 72% chance on the Australian central bank holding rates at 3.6% during its April meeting, up from 52% last week.

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In September 2022, Hancock & Gore’s Joseph Constable selected financial services provider Centrepoint Alliance as one of his favourite stocks, highlighting how…

Thinking of ‘cycling through the streets of Paris’ paints a near perfect picture of charming laneways with an abundance of cafés, the sounds of an accordion bouncing off stone buildings rich with architecture and – if one business owner has anything to do with it – funerals.

In the lead up to this week’s The Insider: Meet the Fund Manager, Jai Mirchandani from ELM Responsible Investments sat down with Reach Markets to provide a bit of information about his investment strategy, methods of ESG analysis, industries of interest and view on the market.

Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for its targeted cell therapy PTX-100 that now extends to all T-cell lymphomas (TCLs). This is an encouraging signal from the US regulatory agency, who had already awarded the asset ODD for its potential to treat Peripheral T-cell Lymphoma – and aggressive cancer with an average 5-year survival rate of 32%.

Happy International Women’s Day! I’d like to acknowledge the immense talent, skills, determination and strength that women contribute to Reach.